Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juni 2025

Genmab — Juni 2025

Planlagt Fastgjort Låst Flyttet Genmab
266 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • G Offline
    G Offline
    gentogen
    wrote on sidst redigeret af
    #174

    Thanks EL for the link 15:24 yesterday. Pure KYSO...

    1 Reply Last reply
    0
    • Helge_LarsenPI-redaktørH Offline
      Helge_LarsenPI-redaktørH Offline
      Helge_LarsenPI-redaktør
      wrote on sidst redigeret af
      #175

      Oversigt: Ny udgave af ØU Life Science – Genmab accelererer mod blockbusterstatus med Rina-S efter data
      https://proinvestor.com/investornyt/1328695/oversigt-ny-udgave-af-ou-life-science-genmab-accelererer-mod-blockbusterstatus-med-rina-s-efter-data

      1 Reply Last reply
      0
      • Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktør
        wrote on sidst redigeret af
        #176

        (Artiklen om Genmab kræver ikke abonnement)

        1 Reply Last reply
        0
        • BudweisB Offline
          BudweisB Offline
          Budweis
          wrote on sidst redigeret af
          #177

          Ser lovende ud https://ml-eu.globenewswire.com/Resource/Download/0b2cf0bd-906b-4985-b4ad-f7d8b772b972

          1 Reply Last reply
          0
          • BudweisB Offline
            BudweisB Offline
            Budweis
            wrote on sidst redigeret af
            #178

            Genmab Announces Epcoritamab Investigational Combination Therapy
            Demonstrates High Response Rates in Patients with Relapsed or
            Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for
            Autologous Stem Cell Transplantation (ASCT)

            1 Reply Last reply
            0
            • J Offline
              J Offline
              JKY_VH
              wrote on sidst redigeret af
              #179

              Super og mange tak for den Budweis:-)

              1 Reply Last reply
              0
              • BulderB Offline
                BulderB Offline
                Bulder
                wrote on sidst redigeret af
                #180

                Epco fortsætter sin sejrsgang. Det bliver stort - ad åre.

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #181

                  Lymphoma Hub
                  @lymphomahub
                  CONGRESS | #EHA2025 | PRESENTATION
                  Daniel Kerr,
                  @TGHCares presents updated results from the epcoritamab + pola-R-CHP cohort of the phase Ib/II EPCORE NHL-5
                  trial (N = 37). https://x.com/lymphomahub/status/1934185493723263388

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #182

                    "These promising results compare favorably to other regimens in 1L and may provide higher cure rates for patients with 1L DLBCL than SOC", suggesting that further exploration is warranted.

                    1 Reply Last reply
                    0
                    • Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktør
                      wrote on sidst redigeret af
                      #183

                      Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) https://proinvestor.com/investornyt/1329270/genmab-announces-epcoritamab-investigational-combination-therapy-demonstrates-high-response-rates-in-patients-with-relapsed-or-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-eligible-for-autologous-stem-cell-trans

                      1 Reply Last reply
                      0
                      • SolsenS Offline
                        SolsenS Offline
                        Solsen
                        wrote on sidst redigeret af
                        #184

                        🙂

                        1 Reply Last reply
                        0
                        • SolsenS Offline
                          SolsenS Offline
                          Solsen
                          wrote on sidst redigeret af
                          #185

                          https://finance.yahoo.com/news/investigational-combination-first-class-bispecifics-071500581.html Flotte resultater på Genmab bispecific vi ser i NHL og MM. Specielt imponerede med epco i first line kombo.

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #186

                            Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease https://finance.yahoo.com/news/investigational-combination-first-class-bispecifics-071500581.html

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #187

                              sry that's the same one lol

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #188

                                Fixed-Duration Epcoritamab Plus Pola-R-CHP Demonstrates Durable Efficacy in First-Line DLBCL https://www.onclive.com/view/fixed-duration-epcoritamab-plus-pola-r-chp-demonstrates-durable-efficacy-in-first-line-dlbcl

                                1 Reply Last reply
                                0
                                • P Offline
                                  P Offline
                                  ProinvestorNEWS
                                  wrote on sidst redigeret af
                                  #189

                                  Genmab har lovende resultater med kræftmiddel i lymfekræftform https://proinvestor.com/investornyt/1329375/genmab-har-lovende-resultater-med-kraeftmiddel-i-lymfekraeftform

                                  1 Reply Last reply
                                  0
                                  • G Offline
                                    G Offline
                                    gentogen
                                    wrote on sidst redigeret af
                                    #190

                                    "Lovende" er da vist en underdrivelse...

                                    1 Reply Last reply
                                    0
                                    • R Offline
                                      R Offline
                                      Raun
                                      wrote on sidst redigeret af
                                      #191

                                      Ja enig - det er jo vildt imponerende 🙂

                                      1 Reply Last reply
                                      0
                                      • wisuwaW Offline
                                        wisuwaW Offline
                                        wisuwa
                                        wrote on sidst redigeret af
                                        #192

                                        Nå... Har været lidt fraværende i Genmab-regi. Hvad ser vi ind i nu? Hvad er kurstriggerne? Og nogle der har regnet på et
                                        EOY kursniveau? 🙂

                                        1 Reply Last reply
                                        0
                                        • Helge_LarsenPI-redaktørH Offline
                                          Helge_LarsenPI-redaktørH Offline
                                          Helge_LarsenPI-redaktør
                                          wrote on sidst redigeret af
                                          #193

                                          Transactions in Connection with Share Buy-back Program https://proinvestor.com/investornyt/1329527/transactions-in-connection-with-share-buy-back-program

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper